NCT07436689
Long-Term Open-Label Extension Study of Oral Levosimendan
StatusEnrolling by Invitation
PhasePhase 3
SponsorTenax Therapeutics, Inc.
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 21, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 9 → 14 locations
- Notable Eligibility criteria expanded, about 7 words
- Primary endpoints: details revised at 1 of 1 entry
- Study sites: 9 to 10
- Minor Study sites: 7 to 9v4
- Minor Study sites: 5 to 7v3
- Minor Start date changed from estimate of Mar 2026 to Mar 13, 2026v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs
Timeframe: From enrollment through study completion (up to 3 years)
Arms and interventions
TNX-103Experimental
Open-label oral levosimendan 1-3mg
Drugs: TNX-103
Sites
14 sites in 2 countries
United States 13, Canada 1